| FDA rejects expanding label of prostate-shrinking drugs to include cancer prevention. |
|
| NY Times: The question before the Food and Drug Administration advisory committee on Tuesday was path-breaking: Would it recommend that the labels of two drugs be changed to say that they can reduce a man’s risk of getting prostate cancer? |